阿帕替尼治疗晚期结直肠癌的安全性和有效性分析

Safety and Efficacy of Apatinib in the Treatment of Advanced Colorectal Cancer

目的观察并分析药物阿帕替尼治疗晚期结直肠癌的临床疗效及其安全性。方法将我院2016年6月至2018年6月收治的80例晚期结直肠癌患者按1:1顺序入组,每组各40例。对照组行对症支持治疗,治疗组行阿帕替尼治疗。比较两组治疗的有效率(RR)、疾病控制率(DCR)和不良反应。结果治疗组的疾病控制率和有效率高于对照组。治疗组不良反应发生率高于对照组(P<0.05),但主要是以1-2级为主,两组比较差异有统计学意义(P<0.05)。结论阿帕替尼可延长晚期结直肠癌患者生存期,不良反应相对较轻且可控制。

Objective To observe and analyze the clinical efficacy and safety of apatinib in the treatment of advanced colorectal cancer.Methods 80 patients with advanced colorectal cancer in our hospital from June 2016 to June 2018 were divided into control group and treatment group according to 1:1 order,40 cases in each group.The control group was treated with symptomatic supportive treatment,and the treatment group was treated with apatinib.The effective rate(RR),disease control rate(DCR)and adverse reactions were compared between the two groups.Results the disease control rate and effective rate of the treatment group were higher than those of the control group.The incidence of adverse reactions in the treatment group was higher than that in the control group(P<0.05),but the main adverse reactions were grade 1-2,with statistical difference between the two groups(P<0.05).Conclusion Apatinib can prolong the survival time of patients with advanced colorectal cancer,and the adverse reactions are relatively mild and controllable.